Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
FAIL · Does not pass the screen
16.92 USD
Price as of 7 Nov 2026Daily close, not a live quote
Screened 2026-11-07 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price16.92 USD at the 7 Nov 2026 close
Our value readUndervalued vs our fair value, as of 7 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.29, read 2026-11-02
Ethical does not pass the values gate
Price16.92 USD
Fair value19.29
Ethical score70.0/100
Value readUndervaluedas of 7 Nov 2026
Our investment reviews on this name
2026-11-07Read Markdown16.92+0.0% to today Accumulation gives way to Markdown first Markdown read since November
2026-11-06Read Accumulation17.07-0.9% to today Markdown gives way to Accumulation after a 6% slide in 1 days
2026-11-05Read Markdown18.18-6.9% to today ✓Accumulation gives way to Markdown first Markdown read since October
2026-11-04Read Accumulation18.27-7.4% to today Markdown gives way to Accumulation after a 12% rise in 7 days
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Omeros Corporation holds its Markdown at $16.92. The statistical read favours the sellers, held for 55 days.
As held on the ledger · 2026-11-07
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 55 days
Price at the screen
$16.92
Valuation
13.87 trailing · 13.76 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.99
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
73.44%
Below 33%
Interest-bearing debt is 73.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
49.79%
Below 33%
Interest-bearing cash and securities are 49.8% of assets, above the one-third limit.
Fail
Receivables
4.95%
Below 49%
Money owed to the company is 4.9% of assets, under the 49% limit.
Pass
Revenue purity
5.99%
Below 5%
6.0% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Omeros's business is in a permissible area, but its interest-bearing debt is about 73% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when OMER's ethical verdict changes
Today OMER does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 7 Nov 2026: it trades at roughly a 12% discount to our $19.29 fair value.
Fair value range in USD, drawn from the 2026-11-07 screen. The gold marker is the market price at the same screen. A 12.3% discount to the base estimate.
Where our models see it going: fair-value estimate $19.29, with a range of $19.29 to $22.18, dated to the 2026-11-07 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it stands out
Trading at 13.8x forward earnings. That is a 12% discount to our $19.29 fair value: the market is pricing it cautiously while the fundamentals argue otherwise.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
OMER trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-07Markdown · changed$16.92-0.9%Entry 13
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 163%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it buy, with a mean price target of $40. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 6.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 163%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it buy, with a mean price target of $40. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-05Markdown · changed$18.18-0.5%Entry 11
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 163%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it buy, with a mean price target of $40. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 12.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 163%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it buy, with a mean price target of $40. Insiders have been net sellers over the past quarter.
2026-10-28Markdown · changed$16.29-11.6%Entry 9
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 163%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it buy, with a mean price target of $40. Insiders have been net sellers over the past quarter. Since the last review it its composite score rose.
2026-10-21Accumulation$18.43-7.1%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 7.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 21% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 163%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it buy, with a mean price target of $40. Insiders have been net sellers over the past quarter.
2026-10-14Accumulation$19.83-5.8%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 5.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 15% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 163%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it buy, with a mean price target of $40. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 117.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 15% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 163%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it buy, with a mean price target of $40. Insiders have been net sellers over the past quarter.
2026-09-08Markup$9.69+0.0%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 15% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 163%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it buy, with a mean price target of $40.
2026-08-07Markup · changed$9.69+10.9%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 15% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 163%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it buy, with a mean price target of $40.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.